Abstract
BACKGROUND: The pilot Phase IIb VIKING study suggested that dolutegravir (DTG), an HIV integrase inhibitor (INI), is efficacious in INI-resistant patients at the 50 mg twice-daily dose. However, DTG response was most reduced in subjects carrying resistance-associated mutations at position G140 and Q148. These mutations can cause a 10-20-fold reduced susceptibility to DTG as well as a 96% lower odds of achieving HIV-1 RNA
| Original language | English |
|---|---|
| Pages (from-to) | 69-72 |
| Number of pages | 4 |
| Journal | Antiviral Therapy |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2019 |
Fingerprint Dive into the research topics of 'Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy'. Together they form a unique fingerprint.
Cite this
Ferrari, D., Spagnuolo, V., Manca, M., Bigoloni, A., Muccini, C., Banfi, G., Locatelli, M., & Castagna, A. (2019). Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients: Antiviral therapy. Antiviral Therapy, 24(1), 69-72. https://doi.org/10.3851/IMP3275